BMO Capital Downgrades Pfizer (PFE) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $27.50 +0.33%
Rating Summary:
14 Buy, 20 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 3
Rating Summary:
14 Buy, 20 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 8 | New: 3
Join SI Premium – FREE
BMO Capital downgraded Pfizer (NYSE: PFE) from Outperform to Market Perform with a price target of $33.00 (from $40.00).
For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.
Shares of Pfizer closed at $31.07 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Upgrades Reckitt Benckiser (RKT:LN) (RBGLY) to Buy
- Nomura/Instinet Downgrades POSCO (005490:KS) to Neutral
- UBS Downgrades Inchcape Plc (INCH:LN) to Neutral
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
